Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Coloplast A/S

Cymed MicroSkin manufactures and distributes ostomy pouching systems featuring MicroSkin adhesives, which are transparent, hypoallergenic polyurethane films designed for comfort and security in ostomy care.

Cymed MicroSkin

Vertex Ventures HC invests in healthcare visionaries to develop novel therapeutic approaches, focusing on the healthcare industry, including biopharmaceuticals, medical devices, and digital health.

Vertex Ventures HC

MedTech Careers provides career opportunities in the MedTech industry, focusing on the development of medical devices and solutions that impact healthcare.

MedTech Careers

Coloplast develops products and services for intimate healthcare needs, focusing on ostomy care, continence care, wound and skin care, and interventional urology.

Coloplast

Tracoe Medical GmbH

Coloplast Interventional Urology

Coloplast Wound and Skin Care 

Atos Medical

Comfort Medical, LLC

LILIAL

Coloplast develops products and services to make life easier for people with deeply personal and private medical conditions. These conditions are often associated with trauma and taboo. The more intimate the condition, the greater the requirement to come closer to customers, understand their world and develop solutions that are sensitive to their special needs. We call this intimate healthcare.

Closeness to all customers makes this possible. We listen to better understand needs and respond by finding new ways to do things better together. We lead the way by bringing the best ideas first and fast to market in the form of medical devices and service solutions. 

Deeply private and personal medical conditions are our focus. Our passion to make a real difference to people’s lives is what drives and unites us. Our culture supports high ambitions and releases the full potential of our own people to achieve them. 

Our business includes Ostomy Care, Continence Care, Wound & Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally, employing more than 16,500 people.


Coloplast has officially broken ground in Portugal! ⛏️

Last week, we broke ground at Felgueiras in the Northern part of Portugal, signalling the start of our growth plan to extend our production capabilities throughout Europe, beyond our current operations in Hungary. The new manufacturing site will produce Coloplast’s intermittent catheters used by people suffering from urinary retention, such as people with a spinal cord injury or spina bifida, who are unable to empty their bladder.

Allan Rasmussen, EVP of Global Operations, attended the ground breaking ceremony and expressed his enthusiasm for the new facility: 

“We are very excited to break ground on this new site, which will enable us to provide high-quality intermittent catheters to more people who need them. This facility is not only a strategic investment for our company, but also a testament to our commitment to improving the lives of people with urinary retention. We are proud to be a leader in this field, and we look forward to expanding our presence and impact in Europe and beyond."

The facility is expected to be fully operational by 2026 and will serve the increasing global demand for intermittent catheters, especially in Europe which is the company's largest market. 

#Coloplast #MakingLifeEasier

Today, we are hosting a ‘Meet the Management’ event at our headquarters in Humlebaek!

The event is an opportunity to get a deeper understanding of Coloplast’s performance, strategic initiatives and future plans. 

You can find the more information, including today’s presentations, on this dedicated site: https://lnkd.in/e2QqpnDB 

#Coloplast #MakingLifeEasier #MeetTheManagement

📣 Webinar Alert 📣 Register today for a live interactive discussion on Preparing your ostomy patients for life after home care.

Join us to discuss:
• Successful discharge planning
• Dietary guidelines and lifestyle for patient and caregiver 
• How patients can order supplies after discharge
• Resources for patient and clinician

Date: July 23rd, 2024

Webinar times:
-Option 1: 8:00 AM CT, register here:  https://lnkd.in/gZmPVQpJ

-Option 2: 11:00 AM CT, register here:  
https://lnkd.in/gFKTDw_Q

-Option 3: 8:00 PM CT, register here: 
https://lnkd.in/gi4Y58VR


This event is focused on education and discussion regarding Coloplast products and technologies. It is not intended to constitute medical or business advice or in any way replace the independent medical judgement of trained and licensed physicians with respect to any patient’s needs or circumstances.

Esta noite, o Congresso Nacional em Brasília, está iluminado com projeções para a conscientização sobre a retenção urinária. 
“Liberdade além da mobilidade” é a mensagem central da campanha da Associação Brasileira de Medicina Física e Reabilitação e apoiada pela Coloplast. A campanha tem como objetivo mostrar a todos os desafios enfrentados por quem tem retenção urinária e é incapaz de urinar ou esvaziar completamente a bexiga, e por isso, precisa da ajuda de uma sonda vesical. Mais de 100 mil brasileiros enfrentam essa condição diariamente e juntos, buscamos dar a luz a essa causa, para que todos tenham mais independência e qualidade de vida. #LiberdadeAlemDaMobilidade #RetencaoUrinaria

Tervetuloa NoSCoS 2024 tapahtumaan moikkaamaan meitä ja tutustumaan elämää helpottaviin hoitotarvikeinnovaatioihin! 

Jaakko Mölsä Ulla Salminen Vuokko Vainio Andreas Ryder Mari Lassinpelto Rie Schønemann Christensen  

#coloplast #noscos2024 #makinglifeeasier #luja #peristeenlight

We are expanding our Luja™ portfolio with a next generation catheter for women!

“I am excited that Luja and the Micro-hole Zone Technology will now be available for female catheter users. The new female catheter has 50+ micro-holes, enabling complete bladder emptying in one free flow, and I believe this technology will set a completely new standard in the market,” says our Executive Vice President of Innovation, Nicolai Buhl Andersen.

Urinary tract infections (UTIs) remain a major concern and challenge for men and women using catheters. Flow stops and blockage of conventional catheter eyelets during catheterisation increase the risk of leaving residual urine behind in the bladder, which raises the risk of bacteria growth and is a well-known UTI risk factor.

Luja for female users will launch across all Coloplast’s key markets over the next 12 months, starting in Denmark and Italy in May 2024*.

You can read more about the launch of Luja Female via this link (including references): https://lnkd.in/gmwkYzEH

*Luja for female users is a medical device for which the CE-mark has been affixed. Product availability is subject to the regulatory process of individual countries and is not guaranteed. The product is currently not available in the US. 

#Coloplast #MakingLifeEasier

Metric
Company Name	Coloplast A/S	Cymed MicroSkin	Vertex Ventures HC	MedTech Careers
Symbol	COLO-B
MSH ID	COM:COLOPLAST	COM:CYMEDOSTOMY	COM:VERTEXVENTURESHC	DK:MEDTECHCAREERS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Commercial & Professional Services
Industry	Medical - Instruments & Supplies	Medical Devices	Venture Capital	Healthcare
Country	DK	US	US	DK
Stage
Employee Count	15.93K
Website	coloplast.com	cymedostomy.com	vertexventureshc.com	medtechcareers.dk
LinkedIn	coloplast
Founders

Metric
Market Cap	27.06B
Enterprise Value
Monthly Web Traffic	87.07K
Web Traffic Growth	-0.17
Valuation
Raised Capital

Metric
Revenue	3.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.48B
EBITDA	1.21B
Operating Income	1.05B
Net Income	715.45M
EPS	3.18
Diluted EPS	3.18
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68
Operating Profit Margin	0.27
EBITDA Margin	0.32
Net Profit Margin	0.19
Return on Equity	0.42
Return on Assets	0.10
Return on Capital Employed	0.23

COM:COLOPLAST

Coloplast

Last Close

891.60

25/11 09:40

Market Cap

191.08B

Beta: -

Volume Today

14.13K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	35.22
P/B Ratio	9.74
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	8.41
EV Multiple	23.81

Metric
Days Sales Outstanding
Days Payables Outstanding	57.80
Days Inventory Outstanding	157.08
Operating Cycle	236.45
Cash Conversion Cycle	185.86
Asset Turnover	0.54

Metric
Operating Cash Flow	391.71M
Free Cash Flow	226.59M
Cash Flow to Debt	0.26
Operating Cash Flow/Sales	0.22
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	111.59M
Accounts Receivable	-71.66M
Inventory	520.02M
Goodwill	2.74B
Debt to Capitalization	0.59
Debt to Assets	0.41
Current Ratio	0.61
Quick Ratio	0.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.04
SG&A to Revenue	0.05